Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Immuneering Corp (NASDAQ:IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as CFO earlier this year.
- Now, the biotech is hopping onto NASDAQ with a $112.5 million IPO. At the beginning of this month, the Company penciled in a $100 million IPO raise.
- Immuneering offered 7.5 million shares at $15 apiece, the midpoint of a $14 to $16 range.
- Between $33 million and $38 million will be used to bring Immuneering’s lead candidate, a dual-MEK inhibitor dubbed IMM-1-104, into the clinic for advanced solid tumors in patients harboring RAS mutations, according to the S-1/A.
- Immuneering plans on submitting an IND for that candidate in the first quarter of 2022.
- Another $38 million to $43 million will fund the development of other candidates in oncology and neuroscience.
- Price Action: IMRX opened for trade at $19.50 and traded at $17.63 during the market session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!